236 related articles for article (PubMed ID: 35538810)
1. Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.
Sani E; Prato GD; Zenti MG; Bordugo A; Trombetta M; Bonora E
Endocr Metab Immune Disord Drug Targets; 2022; 22(10):1053-1057. PubMed ID: 35538810
[TBL] [Abstract][Full Text] [Related]
2. Effect of semaglutide on weight loss and glycaemic control in patients with Prader-Willi Syndrome and type 2 diabetes.
Giménez-Palop O; Romero A; Casamitjana L; Pareja R; Rigla M; Caixàs A
Endocrinol Diabetes Nutr (Engl Ed); 2024 Feb; 71(2):83-87. PubMed ID: 38553173
[TBL] [Abstract][Full Text] [Related]
3. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review.
Ng NBH; Low YW; Rajgor DD; Low JM; Lim YY; Loke KY; Lee YS
Clin Endocrinol (Oxf); 2022 Feb; 96(2):144-154. PubMed ID: 34448208
[TBL] [Abstract][Full Text] [Related]
4. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
5. The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome.
Senda M; Ogawa S; Nako K; Okamura M; Sakamoto T; Ito S
Endocr J; 2012; 59(10):889-94. PubMed ID: 22785236
[TBL] [Abstract][Full Text] [Related]
6. Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report.
Candler T; McGregor D; Narayan K; Moudiotis C; Burren CP
J Pediatr Endocrinol Metab; 2020 Jul; 33(7):951-955. PubMed ID: 32447330
[TBL] [Abstract][Full Text] [Related]
7. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy.
Zipf WB
Acta Paediatr Suppl; 1999 Dec; 88(433):115-7. PubMed ID: 10626560
[TBL] [Abstract][Full Text] [Related]
8. [Obesity treatment with liraglutide in a patient with Prader-Willi syndrome: a case report].
Cadena-Obando DA; Molina-Ayala MA; Ferreira-Hermosillo A
Nutr Hosp; 2018 May; 35(3):743-746. PubMed ID: 29974787
[TBL] [Abstract][Full Text] [Related]
9. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
11. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.
Sze L; Purtell L; Jenkins A; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A
J Clin Endocrinol Metab; 2011 Aug; 96(8):E1314-9. PubMed ID: 21632815
[TBL] [Abstract][Full Text] [Related]
12. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
Salehi P; Hsu I; Azen CG; Mittelman SD; Geffner ME; Jeandron D
Pediatr Obes; 2017 Jun; 12(3):221-228. PubMed ID: 27071367
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.
Diene G; Angulo M; Hale PM; Jepsen CH; Hofman PL; Hokken-Koelega A; Ramesh C; Turan S; Tauber M
J Clin Endocrinol Metab; 2022 Dec; 108(1):4-12. PubMed ID: 36181471
[TBL] [Abstract][Full Text] [Related]
14. Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus.
Rodríguez Jiménez B; Rodríguez de Vera Gómez P; Belmonte Lomas S; Mesa Díaz ÁM; Caballero Mateos I; Galán I; Morales Portillo C; Martínez-Brocca MA
Front Endocrinol (Lausanne); 2024; 15():1386542. PubMed ID: 38894744
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide therapy in Prader-Willi syndrome.
Cyganek K; Koblik T; Kozek E; Wojcik M; Starzyk J; Malecki MT
Diabet Med; 2011 Jun; 28(6):755-6. PubMed ID: 21388446
[No Abstract] [Full Text] [Related]
16. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
17. Weight Loss of Over 100 lbs in a Patient of Prader-Willi Syndrome Treated With Glucagon-Like Peptide-1 (GLP-1) Agonists.
Ahmed S; Naz A; K M
Cureus; 2023 Feb; 15(2):e35102. PubMed ID: 36945294
[TBL] [Abstract][Full Text] [Related]
18. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
19. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
Guo X; Zhou Z; Lyu X; Xu H; Zhu H; Pan H; Wang L; Yang H; Gong F
Horm Metab Res; 2022 Jul; 54(7):458-471. PubMed ID: 35512849
[TBL] [Abstract][Full Text] [Related]
20. Metformin therapy for diabetes in Prader-Willi syndrome.
Chan NN; Feher MD; Bridges NA
J R Soc Med; 1998 Nov; 91(11):598. PubMed ID: 10325882
[No Abstract] [Full Text] [Related]
[Next] [New Search]
